Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression. Its therapeutic use is listed as alcohol dependence agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Acomplia, Zimulti and Rimoslim. Its PubChem CID is 104850.
Rimonabant
| CAS No | 168273-06-1 |
|---|---|
| Molecular Formula | C22H21Cl3N4O |
| Molecular Weight | 463.8 g/mol |
| Synonyms | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
The listed CAS number is 168273-06-1.
The listed molecular formula is C22H21Cl3N4O.
The listed molecular weight is 463.8 g/mol.
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide.
The source lists Acomplia, Zimulti and Rimoslim.